Best Pharmaceutical Companies at a Glance: AstraZeneca

Best Pharmaceutical Companies at a Glance: AstraZeneca

AstraZeneca is a global company involved in the discovery, early- and late-stage development to manufacturing and distribution, and the global commercialization of primary care, specialty care-led and specialty care medicines. The company specializes in   Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA) along with Infection, Neuroscience and Gastrointestinal (ING) disease areas. … Continue reading Best Pharmaceutical Companies at a Glance: AstraZeneca

Advertisements
astrazeneca

AstraZeneca expands opportunities for 1st-line lung cancer Immuno-Oncology program

17 January 2017 AstraZeneca has provided an update on its Immuno-Oncology (IO) late-stage clinical development program in 1st-line non-small cell lung cancer (NSCLC), including a refinement of the Phase III MYSTIC trial. The MYSTIC trial was initially designed to assess the benefit of durvalumab monotherapy and durvalumab and tremelimumab (durva + treme) combination therapy versus standard-of-care (SoC) … Continue reading AstraZeneca expands opportunities for 1st-line lung cancer Immuno-Oncology program

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – December 2016

ABOUND Data Explores Safety and Efficacy of ABRAXANE® for the Treatment of Patients with Lung Cancer Dec 6, 2016 Celgene Corporation has announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in patients with advanced non-small cell lung cancer (NSCLC). Interim data presented from the … Continue reading Top Pharma News – December 2016

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma 2016: One Year in Review

Lots of new things happened in the pharmaceutical industry in 2016. At igeahub.com, our mission is to make the pharmaceutical world simple and clear to everyone. We want our readers to have a privileged view on the key player in the healthcare system, and we do our best to keep things simple but highly accurate. The … Continue reading Pharma 2016: One Year in Review

AstraZeneca Logo

US FDA accepts first biologics license application for durvalumab of AstraZeneca for the treatment of patients with bladder cancer

9 December 2016 AstraZeneca and its global biologics research and development arm, MedImmune, have announced that the US Food and Drug Administration (FDA) has accepted the first Biologics License Application (BLA) for durvalumab, a PD-L1 human monoclonal antibody (mAb). FDA has also granted priority review status with a Prescription Drug User Fee Act (PDUFA) set … Continue reading US FDA accepts first biologics license application for durvalumab of AstraZeneca for the treatment of patients with bladder cancer

World's 12 Most Reputable Pharmaceutical

The World’s Most Reputable Pharmaceutical Companies 2016

Customers’ satisfaction is immensely important for the pharmaceutical companies. When these companies focus on innovation and act responsibly, they gain the required trust from the customers all over the world. Based on how good people feel about big pharma, a ranking has been published by the Reputation Institute (RI). Based on the ranking, we have … Continue reading The World’s Most Reputable Pharmaceutical Companies 2016

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma Oncology | Top News – Fall 2016

AbbVie and Bristol-Myers Squibb Collaborate to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen July 25, 2016 AbbVie and Bristol-Myers Squibb Company have announced a clinical trial collaboration for evaluating the safety, efficacy, and tolerability of investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) of AbbVie in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen … Continue reading Pharma Oncology | Top News – Fall 2016

astrazeneca

Lynparza Phase III SOLO-2 trial reveals substantial progression-free survival benefit

26 October 2016 AstraZeneca has announced positive results from the Phase III SOLO-2 trial for determining the effectiveness of Lynparza (olaparib) tablets (300mg twice daily) as a monotherapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer. The results demonstrate a statistically-significant and clinically-meaningful improvement of progression-free survival (PFS) among patients treated with Lynparza compared to placebo. This … Continue reading Lynparza Phase III SOLO-2 trial reveals substantial progression-free survival benefit

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – September and October, 2016

  Bristol-Myers Squibb’s ORENCIA® (abatacept) is Approved by European Commission for the Treatment of Adult Patients with Rheumatoid Arthritis September 6, 2016 Bristol-Myers Squibb Company has announced that the European Commission has approved ORENCIA ® (abatacept) intravenous (IV) infusion and subcutaneous (SC) injection, combined with methotrexate (MTX), for treating highly active and progressive disease in adult patients with rheumatoid … Continue reading Top Pharma News – September and October, 2016

AstraZeneca Logo

Phase III combination trial of Bydureon and Forxiga shows significant benefits in patients with type-2 diabetes

16 September 2016 Positive results from the Phase III DURATION-8 trial confirmed that Bydureon (exenatide extended-release formulation) 2mg once weekly, combining with Forxiga (dapagliflozin) 10mg once daily significantly reduced blood sugar as measured by HbA1c, versus the individual medicines alone in patients with type-2 diabetes ineffectively controlled on metformin. The results were presented today at … Continue reading Phase III combination trial of Bydureon and Forxiga shows significant benefits in patients with type-2 diabetes